Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Tempus, Canopy Biosciences, Lonza, More

Tempus Lens Platform

Tempus has launched Lens, a cloud-based data and analytics platform designed to provide researchers at biotech and pharma companies with short-term, on-demand access to more than 35 petabytes of deidentified clinical and molecular datasets, as well as artificial intelligence analytical tools to accelerate drug discovery and development.

The Lens platform enables users to access, analyze, and build upon Tempus' library of clinical and molecular data, including tumor/normal matched DNA, RNA, and H&E data, in order to create targeted patient cohorts, simulate clinical trials in silico, and rent or license the underlying data to test hypotheses. Through Lens, users can also collaborate to analyze data with Tempus' computational biologists and data scientists. Users can analyze data through a combination of open source and purpose-built Tempus visual analysis tools or a cloud-based data science environment. They can also apply their own proprietary tools to the data, Tempus said.


Canopy Biosciences COVID-19 Immune Response Assay

Canopy Biosciences, a Bruker company, has launched the research-use-only COVID-19 Immune Response Assay for use on Canopy's ZellScannerOne spatial phenotyping instrument. ZellScannerOne enables multiplexed spatial quantification of protein biomarkers in tissue samples and suspended cells. The new assay can spatially profile 18 different protein biomarkers, and the data it generates enables the identification and quantification of 32 distinct cellular phenotypes, including major immune cell types and various cell states. Canopy said the assay will be available initially as a service, with a reagent kit to follow at a later date.


Lonza 4D-Nucleofector Platform

Lonza has launched its next generation 4D-Nucleofector platform for non-viral transfection of a variety of cell types, particularly difficult-to-transfect cells such as immune cells. The Nucleofector technology uses an advanced electroporation approach to target cell nuclei directly. The 4D-Nucleofector Core Unit can operate up to three functional modules, enabling tailored experimental setups and low- to high-volume transfections. A fully integrated 96-well unit is ideal for users with midscale transfection requirements, while an 8-inch touchscreen display enables users to easily set up their experiments and control all functional modules. Optimized protocols are available for more than 750 different cell types, Lonza noted.


For more new products and services, please visit the New Products page on our website.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.